3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1
Interventions
pembrolizumab
109
Paclitaxel
65
Cyclophosphamide
65
Cisplatin
60
Carboplatin
56
Gemcitabine
48
Radiotherapy
45
Nivolumab
44
fludarabine
38
Docetaxel
38
Pemetrexed
33
Dexamethasone
32
Capecitabine
32
Lenalidomide
26
fludarabine phosphate
25
Rituximab
25
Radiation
25
Ipilimumab
25
Doxorubicin
25
Irinotecan
24
Bevacizumab
24
Azacitidine
24
Vorinostat
23
Vincristine
22
Cytarabine
22
Temozolomide
20
Etoposide
20
Oxaliplatin
19
Fluorouracil
19
atezolizumab
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Has results
×
Imlunestrant
×
Clear all
NCT04647487
2025-11-12
EMBER-2
Eli Lilly and Company
Phase 1
Completed
87 enrolled
13 charts